Volume 134, Issue 46 e202212664
Forschungsartikel

Nickel-Catalyzed Defluorinative Asymmetric Cyclization of Fluoroalkyl-Substituted 1,6-Enynes for the Synthesis of Seletracetam

Dr. Kuai Wang

Dr. Kuai Wang

The Institute for Advanced Studies (IAS), Wuhan University, Wuhan, 430072 People's Republic of China

These authors contributed equally to this work.

Search for more papers by this author
Dr. Jiachang Chen

Dr. Jiachang Chen

The Institute for Advanced Studies (IAS), Wuhan University, Wuhan, 430072 People's Republic of China

These authors contributed equally to this work.

Search for more papers by this author
Wenfeng Liu

Wenfeng Liu

The Institute for Advanced Studies (IAS), Wuhan University, Wuhan, 430072 People's Republic of China

These authors contributed equally to this work.

Search for more papers by this author
Prof. Dr. Wangqing Kong

Corresponding Author

Prof. Dr. Wangqing Kong

The Institute for Advanced Studies (IAS), Wuhan University, Wuhan, 430072 People's Republic of China

Search for more papers by this author
First published: 22 September 2022
Citations: 5

Abstract

The introduction of fluorine-containing groups into organic molecules can significantly affect their physical and chemical properties and has long been used as an effective strategy for drug discovery and development. Consequently, the development of catalytic asymmetric methods for the synthesis of fluorine-containing heterocycles is highly desirable and sought after. Herein, we describe a nickel-catalyzed defluorinative asymmetric cyclization of fluoroalkyl-substituted 1,6-enynes, providing an expedient access to synthetically attractive 4-fluorovinyl-substituted 2-pyrrolidones in good yields with remarkable high levels of chemo-, regio-, and enantioselectivities (90–99 % ee,>35 examples). This protocol features readily available starting materials and excellent functional group compatibility, and exhibits complementary regioselectivity. The utility of this strategy was demonstrated in the enantioselective synthesis of the antiepileptic drug Seletracetam.

Conflict of interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.